Erythropoietin Dosing for Anemia in Multiple Myeloma Patients
Introduction to Erythropoietin Therapy
- The European Myeloma Network recommends initiating epoetin alfa at 40,000 U subcutaneously weekly or darbepoetin alfa at 2.25 μg/kg weekly for multiple myeloma patients with symptomatic anemia and hemoglobin <10 g/dL, with careful attention to thromboembolic risk 1, 2
When to Initiate ESA Therapy
- Start ESAs only when hemoglobin falls below 10 g/dL with persistent symptomatic anemia after excluding other reversible causes, as recommended by the European Myeloma Network 1, 2, 3
- Before starting any ESA, evaluate and correct iron deficiency, as functional iron deficiency is a common cause of ESA hyporesponsiveness, according to the European Myeloma Network 1, 2, 3
Standard Dosing Regimens
- The European Myeloma Network recommends epoetin alfa at 40,000 U subcutaneously weekly or darbepoetin alfa at 2.25 μg/kg weekly, with alternative dosing regimens available 1, 2, 4
Dose Escalation for Non-Responders
- Assess response at 4-6 weeks, and escalate dose if hemoglobin increase is <1 g/dL, as recommended by the American Society of Clinical Oncology 4, 3
Dose Reduction and Target Hemoglobin
- Target hemoglobin range is 10-12 g/dL, and do not exceed 12 g/dL due to increased cardiovascular and thromboembolic risks, according to the American Society of Clinical Oncology 4, 1, 3, 2
Critical Safety Considerations for Myeloma Patients
- Multiple myeloma patients on thalidomide or lenalidomide with dexamethasone or doxorubicin have markedly increased thromboembolism risk when receiving ESAs, and implement thromboprophylaxis as recommended by the International Myeloma Society 4, 1, 2
Iron Supplementation Strategy
- Most patients require concurrent IV iron to optimize ESA response and minimize required doses, as recommended by the European Myeloma Network 1, 3, 2